Difference between revisions of "Team:EPFL"

 
(62 intermediate revisions by 5 users not shown)
Line 1: Line 1:
−
{{EPFL/Head}}
+
{{EPFL/Header}}
 
<html>
 
<html>
  
 
<body>
 
<body>
  
−
   <div class="container-fluid bg-1 text-center">
+
   <main>
−
    <h1>CAPOEIRA</h1>
+
−
    <img src="https://static.igem.org/mediawiki/2018/3/3e/T--EPFL--encapsulin.jpg" class="img-circle" alt="encapsulin" width="150" height="150">
+
−
    <h3>Cancer Personalized Encapsulin Immunotherapy and Relapse Assay</h3>
+
−
  </div>
+
  
−
  <div class="container bg-2 text-center">
+
 
−
    <br>
+
 
−
    <a href="https://2018.igem.org/Team:EPFL/Description"><strong>What is CAPOEIRA ?</strong></a>
+
 
−
    <hr>
+
    <!-- Spotlight -->
−
    <p style="font-size:20px;">While cancer is still the disease of the 21st century, new insights and approaches are changing the landscape of cancer therapy. Cancer immunotherapy is becoming a key technique for the successful fight against cancer. The goal of cancer immunotherapy
+
    <section class="slice slice-xl bg-dark">
−
      is to harness the immune system in the fight against cancer. The project that the EPFL 2018 iGEM team is presenting is focused on the development of a new therapeutic approach to target specific types of cancer using immunotherapy methods, with
+
      <div class="container">
−
      a focus on vaccines. Furthermore, the project aims to integrate the personalized medicine approaches, by using patient-specific neoantigens to trigger the immune system and produce the response against cancer. The project is exhaustive and can
+
        <div class="row row-grid align-items-center">
−
      be divided into the following parts:</p>
+
          <div class="col-lg-5">
−
    <br>
+
            <div class="pt-lg-lg pb-lg-sm text-center text-lg-left">
−
    <div class="row">
+
              <h2 class="h1 text-white mb-3">CAPOEIRA</h2>
−
      <div class="col-sm-3">
+
              <p class="lead text-white lh-180">CAncer PersOnalized Encapsulin Immunotherapy and Relapse Assay</p>
−
        <p><strong>Detection of cancer patient specific tumor mutations and neoantigens</strong></p>
+
 
−
        <img src="https://static.igem.org/mediawiki/2018/b/b0/T--EPFL--Detection.png" class="img-circle project_part" alt="detection" width="255" height="255">
+
                          <a href="https://2018.igem.org/Team:EPFL/Description" class="btn btn-white btn-circle btn-translate--hover btn-icon mr-sm-4 scroll-me">
 +
 
 +
                                      <span class="btn-inner--text">Learn more about our project</span>
 +
                                      <span class="btn-inner--icon"><i class="fas fa-angle-right"></i></span>
 +
                                  </a>
 +
            </div>
 +
          </div>
 +
          <div class="col-lg-6 ml-lg-auto text-center">
 +
            <img src="https://static.igem.org/mediawiki/2018/b/b0/T--EPFL--LOGO_INVERT.png" style="width: 300px;">
 +
          </div>
 +
        </div>
 
       </div>
 
       </div>
−
       <div class="col-sm-3">
+
       <div class="shape-container" data-shape-style="curve" data-shape-position="bottom">
−
         <p><strong>Expression of the neoantigens and the adjuvant using encapsulin</strong></p>
+
         <svg class="shape-fill-primary" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 1000 100" preserveAspectRatio="none">
−
        <img src="https://static.igem.org/mediawiki/2018/9/93/T--EPFL--vaccine.png" class="img-circle project_part" alt="Vaccine" width="255" height="255">
+
                <path d="M 0 0 c 0 0 200 50 500 50 s 500 -50 500 -50 v 101 h -1000 v -100 z"></path>
 +
            </svg>
 
       </div>
 
       </div>
−
      <div class="col-sm-3">
+
    </section>
−
         <p><strong>Maturation of dendritic cells and T-cells <br> <br></strong></p>
+
 
−
        <img src="https://static.igem.org/mediawiki/2018/1/1f/T--EPFL--Dendritic.png" class="img-circle project_part" alt="Dendritic" width="255" height="255">
+
 
 +
 
 +
 
 +
 
 +
    <section class="slice slice-xl bg-primary" id="CAP">
 +
      <div class="container">
 +
         <div class="row row-grid align-items-center">
 +
          <div class="col-lg-12">
 +
            <div class="pr-md-4">
 +
              <h3 class="heading h3 text-white text-center"><font size="+2">What is CAPOEIRA ?</font></h2>
 +
              <p class="lead text-white my-4">While Melanoma remains the deadliest form of skin cancer, immunotherapy approaches can harness our immune system to defeat it! Yet, current immuno-treatments suffer from high costs, limited accessibility, and poor specificity. Our project
 +
                “CAPOEIRA”, named after the Brazilian self-defense martial-art, exploits the potential of synthetic biology to develop a personalized, cost-effective, and rapid production scheme for cancer vaccine and point-of-care relapse surveillance.
 +
                First, a bioinformatic pipeline integrating state-of-the-art tools identifies our targets: melanoma neoantigens, the fingerprints of cancer cells. Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments
 +
                presenting the various neoantigen epitopes. This encapsulin vaccine activates dendritic cells which trigger a T-cell attack on the neoantigen-bearing cancer cells. Nevertheless, we don’t underestimate a defeated villain! To detect potential
 +
                relapse, we combine techniques including dumbbell probes, rolling circle amplification, isothermal amplification, and CRISPR-Cas12a to detect circulating tumor miRNA and DNA. Ultimately, CAPOEIRA trains the immune system to fight back!
 +
 
 +
              </p>
 +
            </div>
 +
          </div>
 +
 
 +
          <div class="p-5 rounded bg-primary">
 +
            <a href="#abstract" class="tongue tongue-bottom scroll-me"><i class="fas fa-angle-down"></i></a>
 +
          </div>
 +
 
 +
        </div>
 
       </div>
 
       </div>
−
       <div class="col-sm-3">
+
    </section>
−
         <p><strong>Detection of cancer relapse using liquid biopsies of ctDNA and cancer miRNA</strong></p>
+
 
−
         <img src="https://static.igem.org/mediawiki/2018/3/3c/T--EPFL--follow_up.png" class="img-circle project_part" alt="follow_up" width="255" height="255">
+
 
 +
 
 +
    <section id="abstract" class="slice">
 +
       <div class="container">
 +
        <div class="mb-5 text-center">
 +
          <br>
 +
          <h3 class="heading h3"><font size="+5">This is CAPOEIRA</font></h2>
 +
         </div>
 +
 
 +
 
 +
        <div class="row row-grid align-items-center slice slice-lg">
 +
          <div class="col-lg-5">
 +
            <div class="animate-this">
 +
            <img src="https://static.igem.org/mediawiki/2018/0/01/T--EPFL--bioinfo.svg" class="img-center img-fluid" width="300px">
 +
          </div>
 +
          </div>
 +
          <div class="col-lg-7 ml-lg-auto">
 +
            <div>
 +
              <h2 class="text-center"><font size="+2">Bioinformatics</font></h2>
 +
              <p class="lead text-gray my-4 text-center">
 +
                <font size="+2">First, a bioinformatic pipeline integrating state-of-the-art tools identifies our target: melonoma neoantigens, the fingerprints of cancer cells</font>
 +
              </p>
 +
 
 +
            </div>
 +
          </div>
 +
        </div>
 +
        <br>
 +
        <div class="row row-grid align-items-center slice slice-lg">
 +
          <div class="col-lg-5 order-lg-2 ml-lg-auto">
 +
            <img src="https://static.igem.org/mediawiki/2018/b/b2/T--EPFL--vaccine-logo.svg" class="img-center img-fluid" width="300px">
 +
          </div>
 +
          <div class="col-lg-7 order-lg-1">
 +
            <div class="pr-lg-7">
 +
              <h2 class="text-center"><font size="+2">Vaccine</font></h2>
 +
              <p class="lead text-gray my-4 text-center">
 +
                <font size="+2">Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes</font>
 +
              </p>
 +
 
 +
            </div>
 +
          </div>
 +
        </div>
 +
 
 +
        <div class="row row-grid align-items-center">
 +
          <div class="col-lg-5">
 +
            <img src="https://static.igem.org/mediawiki/2018/4/4a/T--EPFL--DCentier.svg" class="img-center img-fluid" width="300px">
 +
          </div>
 +
          <div class="col-lg-7 ml-lg-auto">
 +
            <div>
 +
              <h2 class="text-center"><font size="+2">Dendritic cell Activation</font></h2>
 +
              <p class="lead text-gray my-4 text-center">
 +
                <font size="+2">This encapsulin vaccine activates dendritic cells which trigger a T-cell attack on the neoantigen bearing cancer cells</font>
 +
              </p>
 +
            </div>
 +
          </div>
 +
         </div>
 +
 
 +
        <div class="row row-grid align-items-center">
 +
          <div class="col-lg-5 order-lg-2 ml-lg-auto">
 +
            <img src="https://static.igem.org/mediawiki/2018/3/3d/T--EPFL--follow_up_logo.svg" class="img-center img-fluid" width="300px">
 +
          </div>
 +
          <div class="col-lg-7 order-lg-1">
 +
            <div class="pr-lg-7">
 +
              <h2 class="text-center"> <font size="+2">Follow-up</font></h2>
 +
              <p class="lead text-gray my-4 text-center">
 +
                <font size="+2">Nevertheless, we don't underestimate a defeated villain! To detect potential relapse we use techniques like CRISPR-Cas12a to detect circulationg tumor miRNA and DNA</font>
 +
              </p>
 +
 
 +
            </div>
 +
          </div>
 +
        </div>
 +
 
 +
<hr style="height:2px;border:none;color:#333;background-color:#333;" >
 
       </div>
 
       </div>
 +
 +
 +
 +
      <section class="slice slice-xl bg-cover bg-size--cover" style="background-image: url('https://static.igem.org/mediawiki/2018/4/4f/T--EPFL--TeamPage.jpeg'); background-position: center top;">
 +
          <div class="container">
 +
              <div class="row justify-content-center">
 +
                  <div class="col-lg-9">
 +
                      <div class="text-center">
 +
                          <h2 class="heading h1 text-white"> </br> </br> </br> Won: <span>Gold Medal</span></br> Nominated for: <span>Best Therapeutic Project</span> and <span>Best Software</br></ul></ui></h2>
 +
                          <div class="btn-container mt-5">
 +
                              <a href="https://2018.igem.org/Team:EPFL/Awards" class="btn btn-white btn-primary btn-circle px-5">Our Awards!</a>
 +
                          </div>
 +
                      </div>
 +
                  </div>
 +
              </div>
 +
          </div>
 +
      </section>
 +
      <div class="container">
 +
 +
<hr style="height:2px;border:none;color:#333;background-color:#333;" >
 +
 +
      <div class="row">
 +
<video class="responsive-video center-margin" style="width: 100%; padding: 30px" controls>
 +
              <source src="https://static.igem.org/mediawiki/2018/7/77/T--EPFL--iGEM_2018_video.mp4" type="video/mp4" >
 +
              </video>
 +
      </div>
 +
 +
 
     </div>
 
     </div>
−
  </div>
 
  
 +
 +
    </section>
 +
 +
  </main>
 
</body>
 
</body>
  
 
</html>
 
</html>
 +
{{EPFL/Footer}}

Latest revision as of 00:21, 8 December 2018

iGEM EPFL 2018

CAPOEIRA

CAncer PersOnalized Encapsulin Immunotherapy and Relapse Assay

Learn more about our project

What is CAPOEIRA ?

While Melanoma remains the deadliest form of skin cancer, immunotherapy approaches can harness our immune system to defeat it! Yet, current immuno-treatments suffer from high costs, limited accessibility, and poor specificity. Our project “CAPOEIRA”, named after the Brazilian self-defense martial-art, exploits the potential of synthetic biology to develop a personalized, cost-effective, and rapid production scheme for cancer vaccine and point-of-care relapse surveillance. First, a bioinformatic pipeline integrating state-of-the-art tools identifies our targets: melanoma neoantigens, the fingerprints of cancer cells. Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes. This encapsulin vaccine activates dendritic cells which trigger a T-cell attack on the neoantigen-bearing cancer cells. Nevertheless, we don’t underestimate a defeated villain! To detect potential relapse, we combine techniques including dumbbell probes, rolling circle amplification, isothermal amplification, and CRISPR-Cas12a to detect circulating tumor miRNA and DNA. Ultimately, CAPOEIRA trains the immune system to fight back!


This is CAPOEIRA

Bioinformatics

First, a bioinformatic pipeline integrating state-of-the-art tools identifies our target: melonoma neoantigens, the fingerprints of cancer cells


Vaccine

Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes

Dendritic cell Activation

This encapsulin vaccine activates dendritic cells which trigger a T-cell attack on the neoantigen bearing cancer cells

Follow-up

Nevertheless, we don't underestimate a defeated villain! To detect potential relapse we use techniques like CRISPR-Cas12a to detect circulationg tumor miRNA and DNA




Won: Gold Medal
Nominated for: Best Therapeutic Project and Best Software

Our Awards!